{"entity":{"id":"nct06049290","kind":"trial","name":"A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma","aka":[],"tldr":"A phase 1/2 trial of LBL-034 for Injection in multiple myeloma, run by Nanjing Leads Biolabs Co.,Ltd, now recruiting.","summary":"A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma is a phase 1/2 interventional study registered as NCT06049290 by Nanjing Leads Biolabs Co.,Ltd, with 342 participants planned, started 2023-10-20 and due to reach its primary completion in 2026-10-20. Interventions recorded: LBL-034 for Injection.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06049290","url":"https://clinicaltrials.gov/study/NCT06049290"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["nanjing-leads-biolabs"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06049290","phase":"1/2","setting":"A Multicenter, Open-label, Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of LBL-034 in Patients With Relapsed/Refractory Multiple Myeloma","sponsor":"Nanjing Leads Biolabs Co.,Ltd","enrolled":342,"outcomes":[]},"route":"/trials/nct06049290/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"company":[{"id":"nanjing-leads-biolabs","kind":"company","name":"Nanjing Leads Biolabs","route":"/companies/nanjing-leads-biolabs/"}]}}